Zymeworks Inc.

ZYME

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001937653

SEC filings (opens in a new tab)

In the last 90 days, Zymeworks Inc. insiders filed 0 open-market purchases and 1 sale; 203 institutions reported holding it in 13F filings for Q2 2026, worth $1.79B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $1.81B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $357.6K in total: 1
13F holdersQ2 2026, −6 vs. previous quarter: 203
13F valueReported value at the end of Q2 2026: $1.79B
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $106.0M; +38.9% year over year
Net income, FY2025: -$81.1M; No comparable prior period
Free cash flow, FY2025: -$34.5M; No comparable prior period
Revenue, Q3 FY2026: $256.5M; +828.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $81.1M (76.6% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 5.91M; Shares sold short
Change: +337.1K; +6.0% vs. previous
Days to cover: 4.25; At average daily volume

Superinvestors holding ZYME, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ZYME at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Zymeworks Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 9, 2026 (view filing)6:28 PM ET	Oct 9	Same day	Schayowitz AdamEVP, Head of R&D	SSale	−13.8K	$25.85	−$357.6K	−37.3%23.2K after
Jan 13, 2026 (view filing)	Jan 12	1 day	Hollywood MarkEVP & Chief Operating Officer	SSale	−6.12K	$22.67	−$138.7K	−4.4%132.9K after
Jan 12, 2026 (view filing)	Jan 12	Same day	Smith Jeffrey T LEVP & Chief Medical Officer	SSale	−9.31K	$22.67	−$211.1K	−25.8%26.7K after
Jan 12, 2026 (view filing)	Jan 12	Same day	Moore Paul AndrewChief Scientific Officer	SSale	−9.56K	$22.67	−$216.7K	−16.5%48.5K after
Jan 12, 2026 (view filing)	Jan 12	Same day	Galbraith KennethChair & CEO	SSale	−30.4K	$22.67	−$689.7K	−11.8%226.8K after
Jan 5, 2026 (view filing)	Jan 5	Same day	Smith Jeffrey T LEVP & Chief Medical Officer	SSale	−10.5K	$25.10	−$264.5K	−36.5%18.4K after
Jan 5, 2026 (view filing)	Jan 5	Same day	Galbraith KennethChair & CEO	SSale	−54.3K	$25.10	−$1.36M	−21.9%193.3K after	2 lots
Jan 5, 2026 (view filing)	Jan 5	Same day	Moore Paul AndrewChief Scientific Officer	SSale	−20.1K	$25.10	−$504.8K	−33.2%40.4K after	2 lots
Dec 22, 2025 (view filing)	Dec 22	Same day	Galbraith KennethChair & CEO	SSale	−47.5K	$27.02	−$1.28M	−26.3%133.3K after
May 19, 2025 (view filing)6:35 PM ET	May 15-19	4 days	Nodelman Oleg and 1 otherDirector, 10% Owner	PPurchase	+55.4K	$11.47	+$635.6K	+0.3%17.9M after	2 lots

Top 10 13F holders, Q2 2026

See all 203 holders

The largest institutional positions in Zymeworks Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ZYME in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
EcoR1 Capital, LLC	22,970,388	$600.4M	29.77%	00.0%	Unchanged
Rubric Capital Management LP	7,000,000	$183.0M	1.68%	00.0%	Unchanged
BlackRock, Inc.	4,251,030	$111.1M	0.00%	−302,858−6.7%	Reduced
Perceptive Advisors LLC	4,182,953	$109.3M	1.70%	+672,875+19.2%	Added
BVF Inc	3,649,142	$95.4M	2.44%	−85,000−2.3%	Reduced
Morgan Stanley	2,231,260	$58.3M	0.00%	−249,308−10.1%	Reduced
BNP PARIBAS ASSET MANAGEMENT Holding S.A.	1,781,116	$46.6M	0.05%	−126,923−6.7%	Reduced
Vanguard Capital Management LLC	1,558,998	$40.8M	0.00%	−146,582−8.6%	Reduced
Assenagon Asset Management S.A.	1,252,027	$32.7M	0.04%	+524,041+72.0%	Added
Nextech Invest, Ltd.	1,113,946	$29.1M	1.38%	00.0%	Unchanged

Holders of 5% or more of ZYME

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Zymeworks Inc..

Largest holders of ZYME from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
EcoR1 Capital, LLC	13D/A	30.70%23.0M shares	0.00 ppfrom 30.70%	Oct 28, 202212 filings	Nov 19, 2025	SEC
Rubric Capital Management LP	13G/A	9.49%7.00M shares	+1.81 ppfrom 7.68%	Nov 13, 20243 filings	May 15, 2026	SEC
Perceptive Advisors LLC	13G	5.40%3.97M shares	–	Feb 14, 20233 filings	Apr 15, 2026	SEC
Biotechnology Value Fund L P	13G/A	5.20%3.94M shares	–	Jan 3, 20233 filings	Nov 14, 2025	SEC